@article{oai:nagasaki-u.repo.nii.ac.jp:00000855,
 author = {Kobayashi, Kazuma and Tetsuo, Hanako and Yamaguchi, Shun and Ito, Shinichiro and Torashima, Yasuhiro and Inoue, Yusuke and Okada, Satomi and Enjoji, Takahiro and Kuba, Sayaka and Kosaka, Taiichiro and Adachi, Tomohiko and Hidaka, Masaaki and Yamanouchi, Kosho and Kanetaka, Kengo and Takatsuki, Mitsuhisa and Eguchi, Susumu},
 issue = {1},
 journal = {Acta medica Nagasakiensia},
 month = {Jun},
 note = {Aim: This study compared the efficacy and safety of Bmab+oral 5-Fluorourasil (Bmab+o-5-FU) including Bmab+Capecitabine (Cape) with that of intensive chemotherapy including L-OHP or CPT-11 for patients with metastatic colorectal cancer (mCRC).
Methods: Between January 2006 and February 2017, 40 elderly (?70 years) chemotherapy-naive patients with mCRC (male/female=22/18; median age, 76.0 years) were retrospectively reviewed. The treatment regimens were Bmab+o-5-FU (n=19)and intensive regimens (n=21). Intensive regimens comprised 17 L-OHP and 4 CPT-11 doublet chemotherapies.
Results: The median progression-free survival (PFS) with Bmab+o-5-FU and intensive regimens was 281 and 215 days, respectively. The median survival time with Bmab+o-5-FU and intensive regimens was 961 and 1,002 days, respectively. No significant differences were observed in the overall survival or PFS between Bmab+o-5-FU and the other regimens. The disease control rate was 94.7% with Bmab+o-5-FU and 81.0% with intensive regimens. The rate of grade ?3 hematologicaladverse events was 5.3% for Bmab+o-5-FU and 15.8% for intensive regimens.
Conclusions: With its similar survival benefit to intensive regimens, high disease control rate and good feasibility, Bmab+o-5-FU seems a fine treatment choice for elderly mCRC patients., Acta medica Nagasakiensia, 64(1), pp.1-7; 2020},
 pages = {1--7},
 title = {Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer},
 volume = {64},
 year = {2020}
}